# A Study of Bevacizumab (Avastin) Versus Placebo in Combination With Capecitabine (Xeloda) and Cisplatin as First-Line Therapy for Advanced Gastric Cancer

> **NCT00887822** · PHASE3 · COMPLETED · sponsor: **Hoffmann-La Roche** · enrollment: 202 (actual)

## Conditions studied

- Gastric Cancer

## Interventions

- **DRUG:** Bevacizumab
- **DRUG:** Placebo
- **DRUG:** Capecitabine
- **DRUG:** Cisplatin

## Key facts

- **NCT ID:** NCT00887822
- **Lead sponsor:** Hoffmann-La Roche
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-03
- **Primary completion:** 2011-05
- **Final completion:** 2014-08
- **Target enrollment:** 202 (ACTUAL)
- **Last updated:** 2017-03-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00887822

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00887822, "A Study of Bevacizumab (Avastin) Versus Placebo in Combination With Capecitabine (Xeloda) and Cisplatin as First-Line Therapy for Advanced Gastric Cancer". Retrieved via AI Analytics 2026-09-03 from https://api.ai-analytics.org/clinical/NCT00887822. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*